Allecra Therapeutics GmbH

The US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign

The US Food and Drug Administration approvals of Day One Biopharmaceuticals, LLC ’s Ojemda (tovorafenib) and ImmunityBio Inc. ’s Anktiva (nogapendekin alfa inbakicept-pmln) last week provided a boos

The month of March will bring eight more chances for the US FDA to approve novel drugs and biologics, potentially providing a corrective to 2024’s slow start for innovative approvals. The number of us